[1]Fauq,AbdulH.;Maharvi,GhulamM.;Sinha,Dola[BioorganicandMedicinalChemistryLetters,2010,vol.20,#10,p.3036-3038]
[1]CurrentPatentAssignee:ATOSSATHERAPEUTICSINC-WO2019/51370,2019,A1Locationinpatent:Page/Pagecolumn85
[1]Patent:WO2019/51370,2019,A1
[1]Patent:WO2019/51370,2019,A1
Title: Pharmacogenetics of anti-estrogen treatment of breast cancer.
Journal: Cancer treatment reviews 20120801
Title: Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Journal: Therapeutic drug monitoring 20120801
Title: Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.
Journal: Breast cancer research and treatment 20120701
Title: Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score.
Journal: Breast cancer research and treatment 20120601
Title: Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.
Journal: Breast cancer research and treatment 20120601
Title: Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.
Journal: Journal of the American Medical Informatics Association : JAMIA 20120101
Title: Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis.
Journal: Journal of cardiovascular pharmacology 20111201
Title: Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
Journal: Clinical pharmacology and therapeutics 20111001
Title: Locating the binding sites of anticancer tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen on bovine serum albumin.
Journal: European journal of medicinal chemistry 20110901
Title: Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820
Title: Personalized tamoxifen: what is the best way forward?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820
Title: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110820
Title: Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin.
Journal: Biochimie 20110701
Title: P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Journal: The Journal of pharmacology and experimental therapeutics 20110601
Title: Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.
Journal: Clinical pharmacology and therapeutics 20110501
Title: Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Journal: British journal of clinical pharmacology 20110501
Title: Development of a methodology to quantify tamoxifen and endoxifen in breast cancer patients by micellar liquid chromatography and validation according to the ICH guidelines.
Journal: Talanta 20110415
Title: Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Journal: Drug metabolism and disposition: the biological fate of chemicals 20110301
Title: Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Journal: Breast cancer research and treatment 20110101
Title: Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Journal: Breast cancer research : BCR 20110101
Title: A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer.
Journal: BMC systems biology 20110101
Title: Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.
Journal: Clinical pharmacology and therapeutics 20101201
Title: Update on CYP2D6 and its impact on tamoxifen therapy.
Journal: Clinical advances in hematology & oncology : H&O 20100801
Title: Orally administered endoxifen is a new therapeutic agent for breast cancer.
Journal: Breast cancer research and treatment 20100701
Title: Coprescription of tamoxifen and medications that inhibit CYP2D6.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100601
Title: Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Journal: Future oncology (London, England) 20100601
Title: A convenient synthesis of (Z)-4-hydroxy-N-desmethyltamoxifen (endoxifen).
Journal: Bioorganic & medicinal chemistry letters 20100515
Title: Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.
Journal: Journal of medicinal chemistry 20100422
Title: Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder.
Journal: Bioorganic & medicinal chemistry letters 20100415
Title: [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Journal: Bulletin du cancer 20100301
Title: CYP2D6 testing in breast cancer: ready for prime time?
Journal: Oncology (Williston Park, N.Y.) 20091201
Title: Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor.
Journal: Oncology (Williston Park, N.Y.) 20091201
Title: CYP2D6 testing for breast cancer patients: is there more to the story?
Journal: Oncology (Williston Park, N.Y.) 20091201
Title: The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Journal: Breast cancer research and treatment 20091101
Title: Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
Journal: Journal of the National Cancer Institute 20091021
Title: Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810
Title: Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed.
Journal: Basic & clinical pharmacology & toxicology 20090501
Title: The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Journal: Cancer research 20090301
Title: Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.
Journal: Cancer research 20090301
Title: Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
Journal: The American journal of psychiatry 20081001
Title: Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20080101
Title: TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.
Journal: Breast cancer research and treatment 20080101
Title: Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20071101
Title: Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20071001
Title: Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
Journal: The Journal of pharmacology and experimental therapeutics 20060801
Title: Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Journal: Cancer chemotherapy and pharmacology 20050501
Title: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Journal: Breast cancer research and treatment 20040501
Title: Elkins P, et al. Characterization of the isomeric configuration and impurities of (Z)-Endoxifen by 2D NMR, high resolution LC-MS, and quantitative HPLC analysis. J Pharm Biomed Anal. 2014 Jan;88:174-9.
Title: Zheng Y, et, al. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos. 2007 Oct;35(10):1942-8.
